OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update [Yahoo! Finance]
ASAHI KAISEI CRP UNSP/ADR (AHKSY)
NASDAQ:AMEX Investor Relations:
asahi-kasei.co.jp/asahi/en/ir
Company Research
Source: Yahoo! Finance
the recent collaboration and license partnership (February 2024) with AbbVie , nor the €5.8 million of R&D Tax credit, providing reinforced financial visibility until 2026. Proprietary clinical pipeline highlights Tedopi®, optimized epitope-based cancer vaccine: dossier and protocol approved by the Food and Drug Administration (FDA) to launch a new confirmatory Phase 3 clinical trial in second-line lung cancer in patients with acquired/secondary resistance to anti-PD(L)1. Completion of patient enrollment in the Phase 2 in pancreatic cancer; ongoing Phase 2 in combination in ovarian cancer and lung cancer. OSE-127/Lusvertikimab, anti-IL-7 receptor monoclonal antibody: completion of patient enrollment in Phase 2 clinical trial in ulcerative colitis; top-line results expected mid-2024. Positive opinion from the European Medicines Agency (EMA) on Orphan Drug Designation for Lusvertikimab in Acute Lymphoblastic Leukemia. OSE-279, proprietary anti-PD1: positive efficacy and safe
Show less
Read more
Impact Snapshot
Event Time:
AHKSY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AHKSY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AHKSY alerts
High impacting ASAHI KAISEI CRP UNSP/ADR news events
Weekly update
A roundup of the hottest topics
AHKSY
News
- Bionova Scientific, U.S. biologics CDMO of the Asahi Kasei Group, to establish a facility in Texas and launch plasmid DNA businessBusiness Wire
- AKM Achieves Successful Proof of Concept for eFuse in High Voltage 800 V Automotive ApplicationsBusiness Wire
- Asahi Kasei Medical completes new assembly plant for Planova™ virus removal filtersBusiness Wire
- Asahi Kasei to Acquire Calliditas Therapeutics AB to Accelerate Growth as a Global Healthcare CompanyBusiness Wire
- Asahi Kasei Announces Port Colborne, Ontario, Canada as Location of Future Lithium-ion Battery Separator Plant [Yahoo! Finance]Yahoo! Finance